| T2DM (n = 27) | T2DM-HT (n = 23) | Control (n = 31) | P value |
---|---|---|---|---|
Age (years) | 54.1 ± 7.5 | 56.8 ± 6.5 | 54.1 ± 6.2 | 0.271 |
Male, n (%) | 16(59.3) | 12(52.2) | 16(51.6) | 0.819 |
BMI (kg/m2) | 25.2 ± 3.4 | 26.1 ± 2.8$ | 24.2 ± 2.0 | 0.042 |
Diabetes duration (y) | 8.0 ± 2.8 | 8.7 ± 3.1 | – | 0.673 |
Duration of hypertension (y) | – | 4.8 ± 1.2 | – | – |
SBP (mmHg) | 122.5 ± 7.9 | 131.7 ± 9.8$ | 123.9 ± 9.1 | <0.001 |
DBP (mmHg) | 73.9 ± 6.7 | 84.2 ± 8.6$ | 74.9 ± 8.0 | <0.001 |
BUN (mmol/L) | 5.2 ± 1.2 | 5.4 ± 1.9 | – | 0.059 |
creatinine (μmol/L) | 69.0 ± 15.3 | 68.8 ± 14.2 | – | 0.527 |
Total cholesterol (mmol/L) | 4.3 ± 0.9 | 4.5 ± 1.0 | – | 0.630 |
Triglycerides (mmol/L) | 1.6 ± 1.5 | 1.6 ± 0.9 | – | 0.263 |
HDL-C (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.3 | – | 0.986 |
LDL-C (mmol/L) | 2.4 ± 0.7 | 2.7 ± 0.7 | – | 0.575 |
FPG (mmol/L) | 8.1 ± 3.6 | 8.5 ± 2.9 | – | 0.596 |
Hemoglobin A1C (%) | 9.4 ± 2.4 | 8.3 ± 2.2 | – | 0.639 |
Microalbuminuria (MA) | 11.5 ± 6.3 | 9.0 ± 6.3 | – | 0.483 |
Diabetic complication, n (%) | ||||
 Retinopathy | 7(25.9) | 4(17.4) | – | 0.353 |
 Neuropathy | 5(18.5) | 3(13) | – | 0.448 |
 Peripheral vascular disease | 4(14.8) | 6(26.1) | – | 0.261 |
Hypoglycemic medication, n (%) | ||||
 Insulin | 13(48.1) | 10(43.5) | – | 0.482 |
 Metformin | 16(59.3) | 13(56.5) | – | 0.569 |
 Sulphonylurea | 4(14.8) | 6(26.1) | – | 0.261 |
Other medication, n (%) | ||||
 Statin | 8(29.6) | 6(26.1) | – | 0.517 |
 Aspirin | 7(25.9) | 10(43.5) | – | 0.157 |
Antihypertensive medication, n (%) | ||||
 ACEI | – | 11(47.8) | – | – |
 Diuretics | – | 8 (34.7) | – | – |
 Calcium channel blockers | – | 3 (13.0) | – | – |
 β-blockers | – | 4 (17.4) | – | – |